EG01449
EG01449 is a quinoline-based antagonist of Neuropilin-1 (NRP1) with an Kd of 0.6 µM. EG01449 competitively inhibits the binding of VEGFA to NRP1 with an IC50 of 362 nM. EG01449 prevents VEGFA-induced pain by inhibiting NRP1-dependent signaling and reducing sodium currents in sensory neurons. EG01449 can be used for the research of nociceptive pain[1].
Product Specifications
UNSPSC
12352005
Target
VEGFR
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Smiles
O=C([C@H](CCCNC(N)=N)NC(C1=C(C=CS1)NS(=O)(C2=C3N=CC=CC3=CC(NCC4=CSC(N5CCNCC5)=N4)=C2)=O)=O)O.O=CO
Molecular Formula
C29H36N10O7S3
Molecular Weight
732.85
References & Citations
[1]Hestehave S, et al. Quinoline-Based Neuropilin‑1 Antagonists Exhibit a Pure Antagonist Profile and Block Vascular Endothelial Growth Factor-Induced Pain. ACS Pharmacol Transl Sci. 2025;8 (11) :3844-3871. Published 2025 Oct 29.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
